Navigation Links
Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
Date:8/6/2014

LONDON, Aug. 6, 2014 /PRNewswire/ -- LON-ReportbuyerReportbuyer.com has added a new market research report:

Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

http://www.reportbuyer.com/pharma_healthcare/therapeutic/antibacterial_drugs_market_by_class_pipeline_analysis_global_industry_analysis_size_share_growth_trends_forecast_2013_2019.html

Antibacterial Drugs Market (By Class - Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols, and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs, namely, aminoglycosides, B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides and phenicols. The market for these classes has been extensively analyzed on the basis of the leading drug launch, expiry, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2011 to 2019, considering 2012 as the base year. The report on antibacterial drugs market also provides % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019.

Geographically, the antibacterial drugs market has been categorized into four regions namely, North America, Europe, Asia-Pacific, and Rest of the World (ROW). The market sizes and forecasts for each of these regions has been provided for the period 2011 to 2019 along with CAGR (%) for the forecast period 2013 to 2019. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global antibacterial drugs market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis and Porter's five forces analysis for the antibacterial drugs market.

This report includes a chapter on competitive landscape which includes market share analysis of the leading players in the antibacterial drugs market, in terms of percentage share in the year 2012. A list of recommendations has also been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report also comprises a section on pipeline analysis for this market that includes sales forecast for various drugs currently under phase III clinical trials and expected to be launched during the forecast period.

The report also profiles major players of the antibacterial drugs market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Some of the major players profiled in this report include AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Forest Laboratories, Inc., GlaxoSmithKline plc, Merck & Co., Inc. and other significant players.

The global antibacterial drugs market is segmented as follows:

Antibacterial Drugs Market, by Class

Aminoglycosides
B-Lactams
Tetracyclines
Sulfonamides
Quinolones/Fluoroquinolones
Macrolides
Phenicols

Antibacterial Drugs Market, by Geography

North America
Europe
Asia-Pacific
Rest of the World (RoW)

Table of Content

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.3.1.1 Secondary Research
1.3.1.2 Primary Research

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction to Antibacterial Drugs
3.2 Market Trends and Future Outlook
3.2.1 Impact of generics
3.3 Market Drivers
3.3.1 Global increasing prevalence of a large number of infectious diseases
3.3.2 Rising demand for effective and affordable antibacterial drugs from emerging economies
3.3.3 Aging population
3.4 Market Restraints
3.4.1 Weak pipeline of novel antibacterial drugs
3.4.2 Patent expirations
3.4.3 Rising number of generic drugs in various antibacterial drug classes

3.4.4 Increasing number of multi-drug resistant bacterial strains
3.5 Market Opportunities
3.5.1 Product differentiation through technological innovation, use of monoclonal antibodies (mAbs), combination products, new formulations and indications
3.5.2 Product development through partnerships
3.6 Porter's Five Forces Analysis for the Global Antibacterial Drugs Market
3.6.1 Bargaining power of suppliers
3.6.2 Bargaining power of buyers
3.6.3 Threat of substitutes
3.6.4 Threat of new entrants
3.6.5 Competitive rivalry
3.7 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography

Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million)
4.1 Overview
4.1.1 Global Antibacterial Drugs Market Revenue, by Class, 2011 – 2019 (USD Million)
4.1.2 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Class, 2012 & 2019 (Value %)
4.2 Aminoglycosides
4.2.1 Global Aminoglycosides Market Revenue, 2011 – 2019 (USD Million)
4.3 B-Lactams
4.3.1 Global B-Lactams Market Revenue, 2011 – 2019 (USD Million)
4.3.2 Penicillins
4.3.3 Carbapenems

4.3.4 Cephalosporins
4.4 Tetracyclines
4.4.1 Global Tetracyclines Market Revenue, 2011 – 2019 (USD Million)
4.5 Sulfonamides
4.5.1 Global Sulfonamides Market Revenue, 2011 – 2019 (USD Million)
4.6 Quinolones/Fluoroquinolones
4.6.1 Global Quinolones/Fluoroquinolones Market Revenue, 2011 – 2019 (USD Million)
4.7 Macrolides
4.7.1 Global Macrolides Market Revenue, 2011 – 2019 (USD Million)
4.8 Phenicols
4.8.1 Global Phenicols Market Revenue, 2011 – 2019 (USD Million)

Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million)
5.1 Overview
5.2 Delafloxacin (RX-3341)
5.2.1 Global Delafloxacin Market, 2015 – 2019 (USD Million)
5.3 Surotomycin (CB-315)
5.3.1 Global Surotomycin Market, 2016 – 2019 (USD Million)
5.4 Tedizolid (TR-701)
5.4.1 Global Tedizolid Market, 2015 – 2019 (USD Million)
5.5 Ceftolozane/Tazobactam
5.5.1 Global Ceftolozane/Tazobactam Market, 2015 – 2019 (USD Million)
5.6 Dalvance (dalbavancin)
5.6.1 Global Dalvance (dalbavancin) Market, 2015 – 2019 (USD Million)
5.7 Eravacycline (TP-434)
5.7.1 Global Eravacycline Market, 2016 – 2019 (USD Million)

5.8 Delamanid (OPC-67683)
5.8.1 Global Delamanid Market, 2017 – 2019 (USD Million)
5.9 CAZ AVI
5.9.1 Global CAZ AVI Market, 2015 – 2019 (USD Million)
5.10 Solithromycin (CEM-101)
5.10.1 Global Solithromycin Market, 2016 – 2019 (USD Million)
5.11 MK-3415A
5.11.1 Global MK-3415A Market, 2016 – 2019 (USD Million)
5.12 Oritavancin
5.12.1 Global Oritavancin Market, 2015 – 2019 (USD Million)

Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million)
6.1 Overview
6.1.1 Global Antibacterial Drugs Market Revenue, by Geography, 2011 – 2019 (USD Million)
6.1.2 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Geography, 2012 & 2019 (Value %)
6.2 North America
6.2.1 North America Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.3 Europe
6.3.1 Europe Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.4 Asia-Pacific
6.4.1 Asia-Pacific Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 RoW Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis: Global Antibacterial Drugs Market (2012)

Chapter 8 Recommendations
8.1 Development of combination products
8.2 Generic pharmaceuticals: Targeting emerging markets such as India, China, Brazil, Mexico and South Africa
8.3 Strategic collaborations with small biotechnology and research companies

Chapter 9 Company Profiles
9.1 AstraZeneca plc
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.1.5 Recent Developments
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.2.5 Recent Developments
9.3 Bristol-Myers Squibb Company
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.3.5 Recent Developments
9.4 Eli Lilly and Company
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.4.5 Recent Developments
9.5 Forest Laboratories, Inc.
9.5.1 Company Overview

9.5.2 Financial Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.5.5 Recent Developments
9.6 GlaxoSmithKline plc
9.6.1 Company Overview
9.6.2 Financial Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.6.5 Recent Developments
9.7 Johnson & Johnson

9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.7.5 Recent Developments
9.8 Merck & Co., Inc.
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.8.5 Recent Developments
9.9 Novartis AG
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.9.5 Recent Developments
9.10 Pfizer, Inc.
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.10.5 Recent Developments
9.11 Sanofi
9.11.1 Company Overview
9.11.2 Financial Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.11.5 Recent Developments

List of Figures

FIG. 1 Antibacterial Drugs: Market Segmentation
FIG. 2 Global Antibacterial Drugs Market, by Class, 2012 (USD Million)
FIG. 3 Porter's Five Forces Analysis: Global Antibacterial Drugs Market
FIG. 4 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography (2012)
FIG. 5 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Class, 2012 & 2019 (Value %)
FIG. 6 Global Aminoglycosides Market Revenue, 2011 – 2019 (USD Million)
FIG. 7 Global ?-Lactams Market Revenue, 2011 – 2019 (USD Million)
FIG. 8 Global Tetracyclines Market Revenue, 2011 – 2019 (USD Million)
FIG. 9 Global Sulfonamides Market Revenue, 2011 – 2019 (USD Million)
FIG. 10 Global Quinolones/Fluoroquinolones Market Revenue, 2011 – 2019 (USD Million)
FIG. 11 Global Macrolides Market Revenue, 2011 – 2019 (USD Million)
FIG. 12 Global Phenicols Market Revenue, 2011 – 2019 (USD Million)
FIG. 13 Global Delafloxacin Market, 2015 – 2019 (USD Million)
FIG. 14 Global Surotomycin Market, 2016 – 2019 (USD Million)
FIG. 15 Global Tedizolid Market, 2015 – 2019 (USD Million)
FIG. 16 Global Ceftolozane/Tazobactam Market, 2015 – 2019 (USD Million)

FIG. 17 Global Dalvance (Dalbavancin) Market, 2015 – 2019 (USD Million)
FIG. 18 Global Eravacycline Market, 2016 – 2019 (USD Million)
FIG. 19 Global Delamanid Market, 2017 – 2019 (USD Million)
FIG. 20 Global CAZ AVI Market, 2015 – 2019 (USD Million)
FIG. 21 Global Solithromycin Market, 2016 – 2019 (USD Million)
FIG. 22 Global MK-3415A Market, 2016 – 2019 (USD Million)
FIG. 23 Global Oritavancin Market, 2015 – 2019 (USD Million)
FIG. 24 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Geography, 2012 & 2019 (Value %)
FIG. 25 North America Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 26 Europe Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 27 Asia-Pacific Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 28 RoW Antibacterial Drugs Market Revenue, 2011 – 2019 (USD Million)
FIG. 29 Market Share by Key Players: Global Antibacterial Drugs Market, 2012 (%)
FIG. 30 Annual Revenue: AstraZeneca plc, 2010 – 2012 (USD Million)
FIG. 31 Annual Revenue: Bayer AG, 2010 – 2012 (USD Million)
FIG. 32 Annual Revenue: Bristol-Myers Squibb Company 2010 – 2012 (USD Million)
FIG. 33 Annual Revenue: Eli Lilly and Company 2010 – 2012 (USD Million)
FIG. 34 Annual Revenue: Forest Laboratories, Inc., 2010 – 2012 (USD Million)
FIG. 35 Annual Revenue: GlaxoSmithKline plc 2010 – 2012 (USD Million)
FIG. 36 Annual Revenue: Johnson & Johnson 2010 – 2012 (USD Million)
FIG. 37 Annual Revenue: Merck & Co., Inc. 2010 – 2012 (USD Million)
FIG. 38 Annual Revenue: Novartis AG 2010 – 2012 (USD Million)
FIG. 39 Annual Revenue: Pfizer, Inc. 2010 – 2012 (USD Million)
FIG. 40 Annual Revenue: Sanofi, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Antibacterial Drugs Market
TABLE 2 Global Antibacterial Drugs Market Revenue, by Class, 2011 – 2019 (USD Million)
TABLE 3 Global Antibacterial Drugs Market Revenue, by Geography, 2011 – 2019 (USD Million)


Read the full report:
Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

http://www.reportbuyer.com/pharma_healthcare/therapeutic/antibacterial_drugs_market_by_class_pipeline_analysis_global_industry_analysis_size_share_growth_trends_forecast_2013_2019.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
2. Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022
3. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
4. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
5. Ophthalmic Drugs: World Market Prospects 2012-2022
6. Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
7. INTAC™ Technology Combats Misuse of Extended Release Drugs
8. Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise
9. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
10. Bilcare and CSIR to Partner on nonClonableID Technology for Authentication of Drugs
11. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016   GS1 US will hold ... them through GS1 Standards implementation to address the requirements ... Device Identification (UDI) rule. Scott Brown ... Gibson , senior director industry development, medical devices, GS1 ... GS1 US --> Scott Brown ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
(Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. ... in biological and chemical manufacturing, and Kodiak Sciences Inc., ... the treatment of retinal disease, announced today agreements for ... agreement, Lonza will manufacture material at multiple sites, including ... --> --> Retinal diseases, ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... is famous for gift giving with flowers, chocolates and other tokens of affection meant to ... more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts - no ... lives they’ve led and the people they’ve touched. , That’s why Give ...
(Date:2/8/2016)... ... 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the families ... teamed up with Citizens Opposed to Domestic Abuse in support of its efforts to ... those victimized by the fear of violence in their own homes, donations may now ...
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some ... to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay ... and detoxifying the body. , A former motivational speaker, Perry A~ has since dedicated ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... this important news! AHCC and the Home Health and Hospice ICD-10 Transition Workgroup ... for official ICD coding guidance and clarifications, to address concerns over the use ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
Breaking Medicine News(10 mins):